Results 21 to 30 of about 5,784 (166)

Gli1 expression in post-vismodegib excision samples.

, 2022
Gli1 expression in post-vismodegib excision samples.
Shelby P. Unsworth (8748393), Christopher A. Andrews (14204716), May P. Chan (14204719), Alon Kahana (197271), Curtis J. Heisel (8748390), Emily A. Eton (14204713), Christina F. Tingle (8748387), Scott C. Bresler (14204722)   +7 more
core   +1 more source

Vismodegib for treatment of periocular basal cell carcinoma – 6-year experience from a tertiary cancer center, [PDF]

Anais Brasileiros de Dermatologia, 2022
Background: The treatment of advanced periocular basal cell carcinomas becomes a challenge as surgery may involve highly mutilating procedures. Vismodegib is the first selective hedgehog inhibitor approved for the treatment of locally advanced tumors or ...
Catarina Xavier, Edgar Lopes, Catarina Bexiga, Cecília Moura, Emanuel Gouveia, Ana Filipa Duarte   +5 more
doaj   +1 more source

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS

Acta Dermato-Venereologica, 2022
Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally ...
Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst, Dirk Schadendorf   +11 more
doaj   +1 more source

Vismodegib treatment enriches for cells with resistant mutations.

, 2022
A) Clinical photos and Gli1 expression (brown dots) in a patient pre- (left panels), post-vismodegib (center panels), and after recurrence (right panels), B) Allele frequency of PTCH1 and SMO variants pre-, post-vismodegib, and after recurrence (*variant
Shelby P. Unsworth (8748393), Christopher A. Andrews (14204716), May P. Chan (14204719), Alon Kahana (197271), Curtis J. Heisel (8748390), Emily A. Eton (14204713), Christina F. Tingle (8748387), Scott C. Bresler (14204722)   +7 more
core   +1 more source

Keratin 5 expression in post-vismodegib excision samples.

, 2022
Keratin 5 expression in post-vismodegib excision samples.
Shelby P. Unsworth (8748393), Christopher A. Andrews (14204716), May P. Chan (14204719), Alon Kahana (197271), Curtis J. Heisel (8748390), Emily A. Eton (14204713), Christina F. Tingle (8748387), Scott C. Bresler (14204722)   +7 more
core   +1 more source

Vismodegib in locally advanced basal cell carcinoma in Slovenia [PDF]

, 2022
Background: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. Objectives: The purpose of this study is to report outcomes of patients with laBCC, with basal
Maša Sever, Ocvirk, Janja, Janja Ocvirk, Mesti, Tanja, Sever, Maša, Tanja Mesti   +5 more
core   +1 more source

Raman Spectroscopy to Monitor the Delivery of a Nano-Formulation of Vismodegib in the Skin

Applied Sciences, 2023
Raman spectroscopy was used to detect low quantities of Vismodegib in the skin after its topical application via transfersomes. Vismodegib is a novel antineoplastic drug approved for oral administration for treatment of basal cell carcinoma ...
Gisela Eliane Gómez, María Natalia Calienni, Silvia del Valle Alonso, Fernando Carlos Alvira, Jorge Montanari   +4 more
doaj   +1 more source

Exogenous Indian hedgehog antagonist damages intervertebral discs homeostasis in adult mice

Journal of Orthopaedic Translation, 2022
Background: Vismodegib, as an exogenous Indian hedgehog (Ihh) antagonist, has been approved by the Food and Drug Administration (FDA) for the clinical treatment of patients with basal cell carcinoma, and previous observations implicate the potential ...
Ran Chen, Ya Tan, Yang Li, Junlan Huang, Liang Kuang, Zhenhong Ni, Haiyang Lan, Rui Long, Yangli Xie, Hangang Chen, Xiaoqing Luo, Lin Chen, Ying Tang, Siru Zhou   +13 more
doaj   +1 more source

An alternative method for the preparation of vismodegib: A tool for an undergraduate laboratory course

Journal of Chemical Research, 2023
Vismodegib is the first hedgehog signaling pathway inhibitor approved by the Food and Drug Administration (FDA) for the treatment of basal-cell carcinoma.
Xuefei Bao, Chuqiao Song, Dan Liu, Guoliang Chen   +3 more
doaj   +1 more source

Vismodegib-Induced Alopecia: Trichoscopic and Confocal Microscopy Evaluation

, 2020
Introduction: Vismodegib is the first-in-class inhibitor of the sonic hedgehog pathway useful in the treatment of locally advanced or metastatic basal cell carcinoma (BCC) that is not amenable to surgery and radiation therapy.
Patri A., Cappello M., Vastarella M., Fabbrocini G., Scalvenzi M., Cantelli M., Mariateresa Cantelli, Gabriella Fabbrocini, Maria Vastarella, Angela Patrì, Massimiliano Scalvenzi, Milena Cappello   +11 more
core   +1 more source